Share Price and Basic Stock Data
Last Updated: February 12, 2026, 8:54 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
JHS Svendgaard Laboratories Ltd operates within the personal care industry, focusing on manufacturing and marketing oral care products. As of the latest data, the company’s stock price stood at ₹11.20, with a market capitalization of ₹97.60 Cr. The company reported sales of ₹84.81 Cr for the fiscal year ending March 2023, showcasing a decline from ₹86.25 Cr in March 2022. The downward trend continued as the trailing twelve months (TTM) revenue slightly improved to ₹93.56 Cr. Quarterly revenue figures highlight fluctuations, with the latest reported sales of ₹18.93 Cr in September 2023, down from ₹21.72 Cr in March 2023. This inconsistency could be attributed to market dynamics and operational challenges, indicating a need for strategic adjustments. The company’s operational profit margin (OPM) has been volatile, improving marginally to 4.08% in the most recent quarter, reflecting a potential recovery phase. Despite the challenges, the company holds significant reserves of ₹88.04 Cr, positioning it to leverage future opportunities in the personal care sector.
Profitability and Efficiency Metrics
JHS Svendgaard’s profitability metrics present a mixed picture, with a recorded net profit of -₹7.94 Cr for FY 2025, a deterioration from -₹4.29 Cr in FY 2022. The company’s profit before tax also reflected a loss of -₹12.51 Cr for FY 2025. The operating profit has been under pressure, showing negative values across multiple periods, with the most recent quarterly figure at ₹0.41 Cr in September 2023. This translates to a negative operating profit margin of 2.17% for that quarter. Efficiency metrics reveal that the company has a cash conversion cycle (CCC) of 63 days, indicating a relatively longer time taken to convert investments into cash flows compared to industry norms. Return on equity (ROE) stood at a modest 10.8%, while return on capital employed (ROCE) was significantly lower at 5.19%. These figures highlight the company’s struggle to generate returns relative to its equity and capital employed, calling for improved operational efficiency and strategic cost management.
Balance Sheet Strength and Financial Ratios
The balance sheet of JHS Svendgaard Laboratories reflects a cautious approach to leverage, with borrowings amounting to ₹10.59 Cr and a total debt-to-equity ratio of 0.02, indicating low financial risk. This low leverage is further supported by a current ratio of 2.18, suggesting good short-term liquidity and the ability to cover current liabilities. However, the interest coverage ratio (ICR) stood at -2.01x, indicating challenges in meeting interest obligations, which raises concerns about sustainable operational performance. The company’s book value per share, which stood at ₹20.18 as of March 2025, reflects a decrease from previous periods, highlighting the erosion of shareholder value. The price-to-book value (P/BV) ratio of 0.55x suggests that the stock is trading at a discount relative to its book value, potentially making it an attractive option for value investors despite ongoing profitability concerns.
Shareholding Pattern and Investor Confidence
The shareholding structure of JHS Svendgaard Laboratories indicates a significant public shareholding at 63.87%, while promoter holdings have declined from 42.23% in December 2022 to 34.56% by September 2025. This reduction may signal waning confidence among promoters, which could affect overall investor sentiment. Foreign institutional investors (FIIs) hold a modest 1.57% stake, while domestic institutional investors (DIIs) have not reported any holdings, highlighting a lack of institutional backing. The number of shareholders decreased from 24,308 in December 2022 to 25,007 in September 2025, suggesting a slight consolidation of ownership. The shift in shareholding dynamics, particularly the decline in promoter stakes, may raise concerns regarding management commitment and investor confidence, necessitating a closer examination of corporate governance practices and strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, JHS Svendgaard Laboratories faces both opportunities and challenges. The company’s strong reserves of ₹88.04 Cr provide a buffer for navigating operational hurdles and potential expansions. However, persistent profitability issues and negative net profits present significant risks that need addressing through improved operational strategies and cost control measures. Market competition in the personal care sector remains fierce, necessitating innovation and effective marketing strategies to regain market share. The current low institutional investor interest could also hinder future capital raising efforts. If the company successfully implements strategic changes to enhance profitability and operational efficiency, it may attract renewed investor interest and stabilize its financial position. Conversely, failure to address these challenges could lead to further declines in market confidence and financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 9,718 Cr. | 299 | 334/190 | 62.9 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 42.5 Cr. | 25.0 | 34.6/22.3 | 83.3 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 107 Cr. | 112 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 497 Cr. | 325 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 9,123 Cr. | 248 | 400/239 | 24.9 | 55.8 | 1.41 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,272.93 Cr | 1,872.59 | 53.82 | 112.70 | 0.85% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 |
| Expenses | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 |
| Operating Profit | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 |
| OPM % | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% | 4.08% |
| Other Income | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 | 1.14 |
| Interest | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.20 |
| Depreciation | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 |
| Profit before tax | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 |
| Tax % | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% | 1,800.00% |
| Net Profit | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.20 |
| EPS in Rs | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 |
Last Updated: December 30, 2025, 9:16 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 22.28 Cr.. The value appears to be declining and may need further review. It has decreased from 23.45 Cr. (Jun 2025) to 22.28 Cr., marking a decrease of 1.17 Cr..
- For Expenses, as of Sep 2025, the value is 21.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 21.79 Cr. (Jun 2025) to 21.37 Cr., marking a decrease of 0.42 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.91 Cr.. The value appears to be declining and may need further review. It has decreased from 1.66 Cr. (Jun 2025) to 0.91 Cr., marking a decrease of 0.75 Cr..
- For OPM %, as of Sep 2025, the value is 4.08%. The value appears to be declining and may need further review. It has decreased from 7.08% (Jun 2025) to 4.08%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 1.14 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 1.14 Cr., marking an increase of 0.14 Cr..
- For Interest, as of Sep 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.16 Cr. (Jun 2025) to 0.20 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 1.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.88 Cr. (Jun 2025) to 1.86 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Jun 2025) to -0.01 Cr., marking a decrease of 0.63 Cr..
- For Tax %, as of Sep 2025, the value is 1,800.00%. The value appears to be increasing, which may not be favorable. It has increased from -69.35% (Jun 2025) to 1,800.00%, marking an increase of 1,869.35%.
- For Net Profit, as of Sep 2025, the value is -0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Jun 2025) to -0.20 Cr., marking a decrease of 1.26 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.02. The value appears to be declining and may need further review. It has decreased from 0.12 (Jun 2025) to -0.02, marking a decrease of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.28 | 55.10 | 99.62 | 104.18 | 140.29 | 123.99 | 139.11 | 100.77 | 86.25 | 84.81 | 70.80 | 92.00 | 93.56 |
| Expenses | 39.06 | 58.95 | 93.11 | 92.45 | 126.34 | 123.89 | 137.40 | 98.80 | 87.09 | 93.88 | 71.73 | 96.01 | 96.12 |
| Operating Profit | -3.78 | -3.85 | 6.51 | 11.73 | 13.95 | 0.10 | 1.71 | 1.97 | -0.84 | -9.07 | -0.93 | -4.01 | -2.56 |
| OPM % | -10.71% | -6.99% | 6.53% | 11.26% | 9.94% | 0.08% | 1.23% | 1.95% | -0.97% | -10.69% | -1.31% | -4.36% | -2.74% |
| Other Income | -2.67 | -5.79 | -17.30 | 0.39 | 32.03 | 5.97 | 3.16 | 7.49 | 9.39 | -7.31 | 4.31 | 0.02 | 0.97 |
| Interest | 14.14 | 0.14 | 0.36 | 0.62 | 0.74 | 1.03 | 1.95 | 1.24 | 1.39 | 0.55 | 0.46 | 0.57 | 0.70 |
| Depreciation | 14.71 | 12.36 | 10.49 | 6.36 | 6.81 | 7.09 | 8.76 | 7.25 | 7.05 | 6.02 | 6.35 | 7.95 | 7.73 |
| Profit before tax | -35.30 | -22.14 | -21.64 | 5.14 | 38.43 | -2.05 | -5.84 | 0.97 | 0.11 | -22.95 | -3.43 | -12.51 | -10.02 |
| Tax % | -18.39% | 0.18% | 0.00% | -326.85% | 32.19% | -18.54% | -16.95% | -39.18% | 4,000.00% | -23.66% | 18.37% | 57.87% | |
| Net Profit | -28.81 | -22.18 | -21.64 | 21.94 | 26.06 | -1.67 | -4.86 | 1.34 | -4.29 | -17.52 | -4.06 | -19.74 | -7.94 |
| EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.92 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 23.01% | 2.43% | 201.39% | 18.78% | -106.41% | -191.02% | 127.57% | -420.15% | -308.39% | 76.83% | -386.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | -20.58% | 198.95% | -182.61% | -125.19% | -84.61% | 318.59% | -547.72% | 111.76% | 385.22% | -463.03% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -8% |
| 3 Years: | 2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -624% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -9% |
| 3 Years: | -23% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: December 10, 2025, 2:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.10 | 24.10 | 37.64 | 44.12 | 60.90 | 60.90 | 60.90 | 64.40 | 64.90 | 78.40 | 78.40 | 85.60 | 85.60 |
| Reserves | 38.01 | 95.50 | 62.95 | 90.25 | 113.36 | 115.94 | 117.10 | 124.30 | 121.00 | 95.44 | 91.49 | 87.12 | 88.04 |
| Borrowings | 54.12 | 18.82 | 2.56 | 2.31 | 2.49 | 7.19 | 8.58 | 7.01 | 6.19 | 2.58 | 5.13 | 6.46 | 10.59 |
| Other Liabilities | 74.19 | 32.93 | 19.26 | 18.57 | 31.59 | 38.54 | 54.88 | 32.72 | 30.01 | 51.81 | 22.04 | 24.62 | 22.67 |
| Total Liabilities | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
| Fixed Assets | 120.88 | 107.89 | 65.10 | 65.00 | 71.41 | 70.81 | 65.63 | 63.22 | 58.52 | 65.07 | 90.41 | 90.33 | 88.32 |
| CWIP | 0.03 | 0.03 | 0.68 | 0.67 | 0.51 | 4.80 | 7.05 | 8.92 | 19.96 | 8.57 | 0.82 | 0.00 | 2.95 |
| Investments | 0.00 | 0.00 | 0.00 | 1.03 | 18.19 | 9.75 | 6.03 | 2.05 | 3.62 | 2.97 | 3.45 | 3.64 | 4.88 |
| Other Assets | 69.51 | 63.43 | 56.63 | 88.55 | 118.23 | 137.21 | 162.75 | 154.24 | 140.00 | 151.62 | 102.38 | 109.83 | 110.75 |
| Total Assets | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 85.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 85.60 Cr..
- For Reserves, as of Sep 2025, the value is 88.04 Cr.. The value appears strong and on an upward trend. It has increased from 87.12 Cr. (Mar 2025) to 88.04 Cr., marking an increase of 0.92 Cr..
- For Borrowings, as of Sep 2025, the value is 10.59 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.46 Cr. (Mar 2025) to 10.59 Cr., marking an increase of 4.13 Cr..
- For Other Liabilities, as of Sep 2025, the value is 22.67 Cr.. The value appears to be improving (decreasing). It has decreased from 24.62 Cr. (Mar 2025) to 22.67 Cr., marking a decrease of 1.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 206.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
- For Fixed Assets, as of Sep 2025, the value is 88.32 Cr.. The value appears to be declining and may need further review. It has decreased from 90.33 Cr. (Mar 2025) to 88.32 Cr., marking a decrease of 2.01 Cr..
- For CWIP, as of Sep 2025, the value is 2.95 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.95 Cr., marking an increase of 2.95 Cr..
- For Investments, as of Sep 2025, the value is 4.88 Cr.. The value appears strong and on an upward trend. It has increased from 3.64 Cr. (Mar 2025) to 4.88 Cr., marking an increase of 1.24 Cr..
- For Other Assets, as of Sep 2025, the value is 110.75 Cr.. The value appears strong and on an upward trend. It has increased from 109.83 Cr. (Mar 2025) to 110.75 Cr., marking an increase of 0.92 Cr..
- For Total Assets, as of Sep 2025, the value is 206.90 Cr.. The value appears strong and on an upward trend. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
Notably, the Reserves (88.04 Cr.) exceed the Borrowings (10.59 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.90 | -22.67 | 3.95 | 9.42 | 11.46 | -7.09 | -6.87 | -5.04 | -7.03 | -11.65 | -6.06 | -10.47 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
| Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
| Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
| Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
| Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
| ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Diluted EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Cash EPS (Rs.) | -1.38 | 0.29 | -1.43 | 0.42 | 1.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Revenue From Operations / Share (Rs.) | 10.75 | 9.03 | 14.82 | 13.29 | 15.65 |
| PBDIT / Share (Rs.) | -0.13 | 0.43 | 0.81 | 1.32 | 1.47 |
| PBIT / Share (Rs.) | -1.06 | -0.37 | -0.33 | 0.23 | 0.34 |
| PBT / Share (Rs.) | -1.46 | -0.43 | -3.37 | 0.01 | 0.15 |
| Net Profit / Share (Rs.) | -2.31 | -0.51 | -2.58 | -0.66 | 0.20 |
| NP After MI And SOA / Share (Rs.) | -2.31 | -0.51 | -2.38 | -0.62 | 0.18 |
| PBDIT Margin (%) | -1.23 | 4.77 | 5.50 | 9.91 | 9.39 |
| PBIT Margin (%) | -9.87 | -4.19 | -2.25 | 1.73 | 2.19 |
| PBT Margin (%) | -13.59 | -4.84 | -22.70 | 0.11 | 0.96 |
| Net Profit Margin (%) | -21.46 | -5.73 | -17.43 | -4.97 | 1.33 |
| NP After MI And SOA Margin (%) | -21.46 | -5.73 | -16.07 | -4.69 | 1.18 |
| Return on Networth / Equity (%) | -11.43 | -2.38 | -8.96 | -2.17 | 0.63 |
| Return on Capital Employeed (%) | -5.14 | -1.70 | -1.09 | 0.73 | 1.07 |
| Return On Assets (%) | -9.81 | -2.05 | -6.54 | -1.82 | 0.52 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.46 | 0.32 | 0.41 | 0.36 | 0.42 |
| Current Ratio (X) | 2.18 | 1.87 | 2.36 | 4.18 | 5.23 |
| Quick Ratio (X) | 1.70 | 1.33 | 2.00 | 3.54 | 4.73 |
| Inventory Turnover Ratio (X) | 7.50 | 3.11 | 4.36 | 5.16 | 8.94 |
| Interest Coverage Ratio (X) | -2.01 | 7.34 | 5.09 | 6.13 | 7.63 |
| Interest Coverage Ratio (Post Tax) (X) | -28.88 | -7.82 | 2.78 | -2.08 | 2.08 |
| Enterprise Value (Cr.) | 81.22 | 121.69 | 70.51 | 136.74 | 117.07 |
| EV / Net Operating Revenue (X) | 0.88 | 1.72 | 0.73 | 1.59 | 1.16 |
| EV / EBITDA (X) | -71.68 | 36.03 | 13.31 | 15.99 | 12.37 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| Price / BV (X) | 0.55 | 0.75 | 0.59 | 0.71 | 0.68 |
| Price / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| EarningsYield | -0.20 | -0.03 | -0.15 | -0.03 | 0.01 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.38. This value is below the healthy minimum of 3. It has decreased from 0.29 (Mar 24) to -1.38, marking a decrease of 1.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.75. It has increased from 9.03 (Mar 24) to 10.75, marking an increase of 1.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to -0.13, marking a decrease of 0.56.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.06. This value is below the healthy minimum of 0. It has decreased from -0.37 (Mar 24) to -1.06, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.46. This value is below the healthy minimum of 0. It has decreased from -0.43 (Mar 24) to -1.46, marking a decrease of 1.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For PBDIT Margin (%), as of Mar 25, the value is -1.23. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 24) to -1.23, marking a decrease of 6.00.
- For PBIT Margin (%), as of Mar 25, the value is -9.87. This value is below the healthy minimum of 10. It has decreased from -4.19 (Mar 24) to -9.87, marking a decrease of 5.68.
- For PBT Margin (%), as of Mar 25, the value is -13.59. This value is below the healthy minimum of 10. It has decreased from -4.84 (Mar 24) to -13.59, marking a decrease of 8.75.
- For Net Profit Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 5. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 8. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.43. This value is below the healthy minimum of 15. It has decreased from -2.38 (Mar 24) to -11.43, marking a decrease of 9.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.14. This value is below the healthy minimum of 10. It has decreased from -1.70 (Mar 24) to -5.14, marking a decrease of 3.44.
- For Return On Assets (%), as of Mar 25, the value is -9.81. This value is below the healthy minimum of 5. It has decreased from -2.05 (Mar 24) to -9.81, marking a decrease of 7.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has increased from 0.32 (Mar 24) to 0.46, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 2.18, marking an increase of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.70, marking an increase of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.50. This value is within the healthy range. It has increased from 3.11 (Mar 24) to 7.50, marking an increase of 4.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.01. This value is below the healthy minimum of 3. It has decreased from 7.34 (Mar 24) to -2.01, marking a decrease of 9.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -28.88. This value is below the healthy minimum of 3. It has decreased from -7.82 (Mar 24) to -28.88, marking a decrease of 21.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 81.22. It has decreased from 121.69 (Mar 24) to 81.22, marking a decrease of 40.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 1.72 (Mar 24) to 0.88, marking a decrease of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is -71.68. This value is below the healthy minimum of 5. It has decreased from 36.03 (Mar 24) to -71.68, marking a decrease of 107.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For Price / BV (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.55, marking a decrease of 0.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.20, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -21.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.14% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.43% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -28.88
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -21.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
| Mr. Nikhil Nanda | Managing & Executive Director |
| Mr. Vinay Mittal | Non Executive Director |
| Mr. Kapil Minocha | Independent Director |
| Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 13 February 2026) is ₹25.46 which is 142.48% higher the current market price of ₹10.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹91.7 Cr. market cap, FY2025-2026 high/low of ₹18.4/8.66, reserves of ₹88.04 Cr, and liabilities of ₹206.90 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 91.7 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 13 February 2026?
The current stock price of JHS Svendgaard Laboratories Ltd as on 13 February 2026 is ₹10.5.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is ₹18.4/8.66.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.3.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.